The Kelley-Gonzalez Protocol: Pancreatic Enzymes, Metabolic Typing, and the Quest to Treat Terminal Cancer

The Kelley-Gonzalez Protocol is an intensive, nutrition-based cancer therapy developed by dentist William Donald Kelley and later refined and championed by physician Nicholas Gonzalez. Rooted in the turn-of-the-century trophoblast theory of cancer, the protocol posits that pancreatic proteolytic enzymes can digest malignant cells and restore the body's natural defenses when combined with a strict, individually tailored diet and a rigorous detoxification program involving coffee enemas. This essay explores the origins of the protocol in Kelley's personal survival story, Gonzalez's monumental five-year investigation of Kelley's records, the complex scientific theories underpinning the therapy, its three core components, the compelling but controversial clinical evidence, and the definitive 2010 clinical trial whose results ultimately positioned the protocol outside mainstream oncology while cementing its legacy in the world of integrative medicine.

---

1. Introduction: The Maverick Dentist and the Physician Who Believed Him

The story of the Kelley-Gonzalez Protocol is a story of two men separated by a generation but united by a shared conviction that the conventional approach to cancer was fundamentally incomplete. William Donald Kelley was a Texas orthodontist who, in the 1960s, received a diagnosis of advanced pancreatic cancer and was given only months to live. Rejecting surgery, radiation, and chemotherapy, Kelley devised his own nutritional and detoxification program. He claimed not only to have survived his own terminal illness but to have thrived, and he spent the subsequent decades treating thousands of cancer patients at his clinic in Dallas and later in Mexico, attracting both fervent followers and fierce criticism from the medical establishment .

Two decades later, Nicholas Gonzalez was a second-year medical student at Cornell University Medical College, a former journalist with a skeptical and investigative mind. Intrigued by Kelley's work and the extraordinary claims surrounding it, Gonzalez embarked on what would become a five-year deep dive into Kelley's patient records, reviewing over 1,000 charts and interviewing more than 400 individuals who had undergone the treatment . What he found convinced him that Kelley, despite his lack of medical credentials and unorthodox methods, had stumbled upon something of profound importance. Gonzalez went on to complete a fellowship in immunology and, alongside his partner Dr. Linda Isaacs, dedicated his career to refining and practicing the protocol, bringing it into a New York City medical practice and, for a time, into the halls of the National Institutes of Health . Their work represents one of the most thorough, well-documented, and controversial challenges to the conventional cancer paradigm from within the world of alternative medicine.

2. The Foundational Philosophy: The Trophoblast Theory and Autonomic Typing

The Kelley-Gonzalez Protocol is built upon two central, interconnected theoretical pillars: the trophoblast theory of cancer and the concept of autonomic nervous system typing. These ideas, largely outside the bounds of conventional oncology, form the entire rationale for the therapy's design.

The Trophoblast Theory of Cancer

The protocol's core mechanism of action derives from a theory first proposed in the early 20th century by the Scottish embryologist John Beard. Beard observed that the trophoblast, the tissue that surrounds a developing embryo and aggressively invades the uterine wall to establish a pregnancy, behaves in a manner strikingly similar to a malignant tumor . He noted a critical coincidence: the trophoblast's invasive growth halts precisely at the point in gestation when the fetal pancreas begins to function and secrete pancreatic enzymes.

From this, Beard theorized that cancer cells are trophoblast cells, or cells that have dedifferentiated into a trophoblast-like state. He further hypothesized that the body's natural defense against this uncontrolled trophoblast growth is the systemic circulation of pancreatic proteolytic enzymes. Cancer, in this view, represents a failure of the body to produce or properly utilize enough pancreatic enzyme to digest and eliminate these rogue cells . The Kelley-Gonzalez Protocol's central intervention—the administration of massive, pharmacologic doses of orally ingested pancreatic enzymes derived from pigs—is a direct translation of Beard's century-old theory into clinical practice .

Autonomic Typing and Individualized Diets

The second pillar of the protocol is the belief that each individual has a dominant branch of their autonomic nervous system—either sympathetic (fight-or-flight) or parasympathetic (rest-and-digest)—that profoundly influences their metabolic needs and how they should eat . Dr. Kelley, based on his observations of patients, developed a system of ten basic metabolic types. He believed that a person's autonomic dominance dictated which diet would be optimally healing for them, with types ranging from near-vegetarian to almost exclusively carnivore .

This concept of "autonomic typing" explains why the protocol is not a one-size-fits-all diet. A patient with a dominant sympathetic system, Kelley argued, required a diet richer in fats and proteins, while a parasympathetic-dominant patient needed more carbohydrates from vegetables and fruits. Gonzalez and Isaacs continued to use this system, believing that providing the body with the right raw materials for its specific metabolic type was essential for creating an internal environment hostile to cancer and supportive of the enzyme therapy's effects .

3. The Three Core Components: A Multi-Pronged Attack

The Kelley-Gonzalez Protocol is an intensive, full-time undertaking for patients, consisting of three integrated components designed to work synergistically.

Pancreatic Enzyme Therapy

The cornerstone of the protocol is the ingestion of massive quantities of freeze-dried pancreatic enzymes, derived from pigs. Patients are typically required to take between 130 and 175 capsules daily, which can amount to 25 to 45 grams of pure enzyme concentrate . The enzymes must be taken on an empty stomach at precise intervals throughout the day to ensure they are absorbed into the bloodstream intact, rather than being used for digestion in the gut. The goal is systemic absorption, allowing the enzymes to circulate and, according to the trophoblast theory, directly digest and dismantle tumor tissue .

Individualized Diet and Nutritional Supplementation

Based on the patient's determined autonomic type, a highly specific diet is prescribed. For some, this may be largely vegetarian, rich in raw and steamed vegetables, fruits, juices, nuts, and seeds. For others, it may include limited amounts of fish or animal products. Common to all versions of the diet is the strict exclusion of processed foods, refined sugar, white flour products, and soy . In addition to the enzymes, patients take a complex regimen of supplements, including high-dose vitamins, minerals, trace elements, amino acids, and glandular extracts—totaling the full 150 to 175 pills per day .

Detoxification: Coffee Enemas

The protocol mandates a rigorous detoxification program, most famously involving coffee enemas. Patients typically administer enemas one to four times daily, often in conjunction with the juice fasts that occur during breaks from the enzyme pills . The rationale, as articulated by both Kelley and Gonzalez, is that as tumors are broken down by the pancreatic enzymes, large quantities of toxic cellular debris and protein wastes are released into the bloodstream. They believed that the caffeine in the coffee enema, absorbed through the rectal wall, stimulates the liver to produce more bile and enhances the body's natural detoxification pathways, helping to neutralize and eliminate these wastes and prevent autotoxicity .

4. The Gonzalez Investigation: From Skeptic to Advocate

The story of how a conventional medical student became the leading proponent of Kelley's work is central to the protocol's narrative. In 1981, Nicholas Gonzalez, then a 33-year-old former journalist and second-year medical student, approached Kelley for what he intended to be a brief research project . Kelley instead opened his entire archive of patient files to him.

For the next five years, Gonzalez immersed himself in Kelley's world. He reviewed over 1,000 medical charts and personally interviewed more than 400 former patients, traveling across the country to meet with them and, whenever possible, verify their medical records and pathology reports . The result of this monumental effort was a 1,500-page monograph, completed in 1986, which presented detailed case histories of 50 patients with poor-prognosis or terminal cancers who, Gonzalez concluded, had done exceptionally well under Kelley's care .

Gonzalez's monograph was his attempt to bring Kelley's work to the attention of the medical establishment. However, for over two decades, he was unable to find a publisher. It was not until 2010 that he self-published the work under the title One Man Alone: An Investigation of Nutrition, Cancer and William Donald Kelley . This book remains the definitive text on the protocol's origins and the foundation for the clinical claims made on its behalf.

5. Clinical Evidence and the Columbia Clinical Trial

The evidence for the Kelley-Gonzalez Protocol is a story of two starkly different data sets: compelling anecdotal cases and a definitive, negative controlled trial.

The Anecdotal Evidence: Fifty Cases

The 50 cases detailed in One Man Alone form the bedrock of the protocol's support . They include patients with pancreatic, lung, breast, ovarian, and other advanced cancers who lived for years, and in some cases decades, beyond their prognoses. Gonzalez provided copies of medical records, pathology reports, and imaging studies to substantiate his claims, and the testimonies of these patients and their families are powerful and affecting .

A 2018 review in the journal Nutrition and Cancer acknowledged that the evidence base for the Gonzalez Protocol consists of Level II evidence (evidence from individual, well-designed clinical studies, like case-control or cohort studies) . However, a detailed analysis published by Quackwatch in 2020 scrutinized these same 50 cases and identified significant methodological problems . The analysis noted that many patients had received some form of conventional treatment (surgery, radiation, or chemotherapy) prior to starting Kelley's protocol, making it impossible to attribute their survival solely to the nutritional therapy. In other cases, the diagnosis itself was questionable, or the outcome was not as unusual as claimed. The review concluded that while a handful of cases were suggestive of a potential effect, none met the stringent criteria required to prove that the Kelley method alone was responsible for a cancer cure .

The 1994 Pilot Study and the Columbia Trial

The anecdotal evidence was strong enough to attract the attention of the National Cancer Institute's Office of Cancer Complementary and Alternative Medicine. In 1994, Gonzalez conducted a small pilot study of his protocol on 11 patients with inoperable pancreatic cancer, one of the most lethal of all cancers. The results were striking: five patients lived longer than two years, and two lived longer than four years . A comparison group of patients treated with standard chemotherapy at the time survived no more than 19 months. These results were published in the journal Nutrition and Cancer and were sufficiently impressive to persuade the NIH to fund a larger, more rigorous trial .

This phase III randomized controlled trial was conducted at Columbia University under the direction of surgical oncologist Dr. John Chabot. It was designed to compare the Gonzalez regimen head-to-head with single-agent gemcitabine chemotherapy in 72 to 90 patients with advanced, inoperable pancreatic cancer . The results, published in the Journal of Clinical Oncology in 2010, were definitive and devastating for the protocol. The trial was stopped early because the patients in the chemotherapy arm were living significantly longer. On average, patients receiving gemcitabine survived 14 months, while those on the Gonzalez regimen survived only 4.3 months . Furthermore, patients on the Gonzalez regimen reported a poorer quality of life than those receiving chemotherapy .

6. The Aftermath and Ongoing Legacy

Following the publication of the Columbia trial results, the Gonzalez protocol was effectively discredited in the eyes of the mainstream medical community. Dr. Chabot, who had admired Gonzalez's devotion, expressed the view that his former colleague was "misguided due to his zealotry" . The National Cancer Institute's PDQ summary on the regimen was updated to note that the information was no longer being updated and was provided for reference purposes only, citing the negative trial results .

Nicholas Gonzalez died unexpectedly in July 2015 at the age of 67 . His death was not widely reported, and its cause was never publicly disclosed, leading to speculation among his followers . However, his work did not end with him. His former partner, Dr. Linda Isaacs, continues to operate a medical practice in New York, offering the Gonzalez protocol to patients who seek a nutritional approach to cancer and other chronic illnesses .

7. Scientific Critique and Controversies

The Kelley-Gonzalez Protocol remains one of the most thoroughly investigated and debated alternative cancer therapies. Its controversies highlight fundamental differences between alternative and conventional medicine.

The Trophoblast Theory is not accepted by modern oncology. The understanding of cancer as a genetic disease of uncontrolled cell division, driven by mutations in oncogenes and tumor suppressor genes, is supported by decades of molecular biology research that has no place for the trophoblast theory.

The Autonomic Typing System has no validated scientific basis. It is an untested hypothesis with no reliable biomarkers to classify patients or predict dietary needs.

The Columbia clinical trial is considered the gold-standard refutation of the protocol's efficacy for pancreatic cancer. Its results are clear, peer-reviewed, and published in a top-tier oncology journal. Proponents, including Dr. Isaacs and some patients, have criticized the trial, arguing that the patients in the Gonzalez arm may have been sicker or that the rigorous nature of the protocol was not properly adhered to by participants . However, these criticisms have not been supported by any published re-analysis of the data.

The cost of the treatment, which can run into tens of thousands of dollars annually and is rarely covered by insurance, has also been a point of ethical concern . For a therapy with no proven efficacy in its most rigorous test, such a financial burden on vulnerable patients is a significant drawback.

8. Conclusion

The Kelley-Gonzalez Protocol stands as a monument to a different way of thinking about cancer—one that sees the disease not as a localized genetic accident but as a systemic metabolic and immune failure requiring a comprehensive, personalized nutritional intervention. From William Kelley's desperate self-experimentation to Nicholas Gonzalez's decade-spanning crusade for legitimacy, the story of this therapy is filled with passion, conviction, and the powerful testimonies of patients who believed their lives were saved.

Yet, for all its rich history and compelling anecdotes, the protocol's scientific foundation rests on a theory abandoned by mainstream science over a century ago. Its most rigorous, independent test—the 2010 Columbia trial funded by the NIH—demonstrated unequivocally that for patients with inoperable pancreatic cancer, the Gonzalez regimen was inferior to a single, standard chemotherapy drug. The patients taking 150 pills a day and administering coffee enemas survived, on average, less than one-third as long as those receiving simple gemcitabine infusions.

The legacy of the Kelley-Gonzalez Protocol is therefore a cautionary and complex one. It serves as a powerful reminder of the desperation that drives patients to seek alternatives when conventional medicine offers little hope. It highlights the enduring power of anecdote and the immense difficulty of proving causation in the face of compelling stories. And it underscores the absolute necessity of rigorous, controlled clinical trials to separate genuine therapeutic breakthroughs from well-intentioned but ultimately ineffective—and even harmful—interventions. Dr. Linda Isaacs continues the work, a small flame kept alive by a community of believers . But for the world of evidence-based medicine, the Gonzalez protocol, despite its fascinating origins and devoted following, remains a treatment that was tested and, by the most reliable measures available, found wanting.

9. Key Published Works and Resources

· Book: One Man Alone: An Investigation of Nutrition, Cancer and William Donald Kelley by Nicholas J. Gonzalez, MD

· Book: The Trophoblast and the Origins of Cancer by Nicholas J. Gonzalez, MD and Linda L. Isaacs, MD

· Clinical Study: Gonzalez NJ, Isaacs LL. "Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support." Nutr Cancer. 1999;33(2):117-24. (The 1994 pilot study)

· Clinical Trial: Chabot JA, et al. "Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer." Journal of Clinical Oncology. 2010;28(15_suppl):4101. (The 2010 Columbia trial results)

· Practice Website: Dr. Linda Isaacs, MD (drlindai.com)